Merck (MRK)
$90.45
0.13 (0.14%)
MRK Stock Quote Delayed 30 Minutes
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Unlock Louis Navellier's
? Stock Report – FREE:
Is ? a BUY?
Powered by Portfolio Grader
A
B
C
D
F
?
Unlock Louis Navellier's
? Stock Report to Find Out – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Investing legend Louis Navellier rates ? a "?." Unlock his ? Stock Analysis to find out why – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Fundamental Grade
Quantitative Grade
- Sales Growth ?
- Operating Margin Growth ?
- Earnings Growth ?
- Earnings Momentum ?
- Earnings Surprises ?
- Analyst Earnings Revisions ?
- Cash Flow ?
- Return on Equity ?
Previous Close
$89.38
Market Cap
226.10B
PE Ratio
13.43
EPS
6.7363
Volume (Avg. Vol.)
10.21M
Day's Range
$89.25 - $90.97
52-Week Range
$81.04 - $132.70
Dividend & Yield
$3.12 (3.45%)
MRK Stock Predictions, Articles, and Merck News
Amid Mixed News on Earnings, Merck & Co., Inc. (MRK) Stock Remains Steady
Merck stock delivered a mixed picture on earnings, and drug trials, but MRK stock will still deliver slow, steady growth to MRK investors.
Pfizer Inc. Stock Is Boring But Great for Your Portfolio’s Health
Fundamentally PFE is too cheap. So go long on this earnings dip inside a nervous market. Management is proven for decades and is bankable for the future.
The Treasury Yield Is Trembling on the Edge of 3%
Earnings season is moving into high gear, and several stocks, including Caterpillar and Merck, saw analyst upgrades on Monday.
Stocks Push Forward As Fears of War Diminish
Stocks climbed again on Monday, shrugging off the U.S.-led airstrike on Syria over the weekend. Now the market will get an update on U.S. industrial production as well as a batch of Federal Reserve policymaker speeches.
3 Reasons to Be Bullish on Merck & Co., Inc. Stock
Merck has had a tough year. But this does look like an opportunity for investors. MRK has a robust pipeline and Keytruda should continue to propel growth.
Expect Stocks to Rise on Continued Bullishness
The bulls blasted stocks higher out of the gate yesterday, and you can expect that to continue today after trade war concerns were dampened by Chinese President Xi Jinping's latest announcement.
Incyte Corporation Stock Plunges on Melanoma Drug Trial Failure
Incyte (INCY) was falling hard on Friday following news of a failed Phase 3 drug trial for its melanoma drug epacadostat.
4 Dow Jones Heavyweights That Are Still on the Ropes
Some headwinds are appearing now, and with trading liquidity still very light, the machines are feeding some selling pressure at current levels. Here are four Dow Jones stocks that could see some trouble as a result.
The Future of Merck & Co., Inc. Stock Is With Keytruda
Merck & Co's cancer drug, Keytruda, saw explosive growth this quarter, making MRK stock a tough name to handicap right now.
Why Investors Should Stay Long Eli Lilly and Co Stock
LLY stock had a sudden drop on Jan. 22, but Eli Lilly and Co recovered the bulk of its losses, which means bulls can stay long for the time being.
Merck & Co., Inc.’s Rally Could Burn Investors
While Merck is riding high on good news from Keynote-189, there's still too much danger to make MRK stock a strong buy.
Adverse Earnings Momentum Make Merck & Co (MRK) a Sell
Merck & Co (NYSE:MRK) is one of the 657 companies in the GICS Health Technology sector, and a component of the 38 company Pharmaceuticals: Major GICS industry group within this sector. MRK has a market value of $159.9 billion which is in the top quarter of its industry group. The stock's current Portfolio Grader ranking places it 38 among the 38 companies in this industry group, a position that is well below-average; squarely in the bottom quartile of the sector with a ranking of 577 among the 657 companies in the sector, and number 4,121 in the nearly 5,000 company Portfolio Grader universe.
Merck & Co., Inc. Stock Could Still Soar Another 10% From Here
Positive Keytruda results have propelled Merck higher over the last week. Buying a pullback is the prudent play for investors in MRK stock.
Merck & Co., Inc. (MRK) Stock Surges on Lung Cancer Drug Success
Merck (MRK) shares were surging Tuesday as the company's latest lung cancer drug yielded positive results, helping patients live longer.
After Irrational Fire Sale, It’s Time to Buy the Dip in Merck & Co., Inc. Stock
Merck is struggling after a supposedly disappointing earnings report, but the resultant selloff in Merck stock is well overdone.
